Cantor Fitzgerald Analysts Give Versartis, Inc. (NASDAQ:VSAR) a $34.00 Price Target
A number of other equities analysts have also commented on VSAR. Piper Jaffray Companies boosted their price objective on shares of Versartis from $22.00 to $26.00 and gave the stock an overweight rating in a report on Tuesday, April 4th. Zacks Investment Research lowered shares of Versartis from a hold rating to a sell rating in a report on Wednesday, May 3rd. Canaccord Genuity set a $28.00 price objective on shares of Versartis and gave the stock a buy rating in a report on Sunday, May 28th. ValuEngine upgraded shares of Versartis from a sell rating to a hold rating in a report on Friday, June 2nd. Finally, BidaskClub lowered shares of Versartis from a buy rating to a hold rating in a report on Sunday, July 16th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of $25.13.
Shares of Versartis (NASDAQ VSAR) opened at 18.80 on Thursday. The firm’s market capitalization is $661.91 million. Versartis has a 1-year low of $9.05 and a 1-year high of $24.00. The firm has a 50-day moving average price of $17.52 and a 200-day moving average price of $17.82.
Versartis (NASDAQ:VSAR) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by $0.20. On average, analysts forecast that Versartis will post ($2.94) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.watchlistnews.com/cantor-fitzgerald-analysts-give-versartis-inc-nasdaqvsar-a-34-00-price-target/1463945.html.
A number of institutional investors have recently modified their holdings of VSAR. Russell Investments Group Ltd. purchased a new position in shares of Versartis during the fourth quarter worth approximately $116,000. State Street Corp raised its stake in shares of Versartis by 17.5% in the fourth quarter. State Street Corp now owns 445,716 shares of the biopharmaceutical company’s stock worth $6,638,000 after buying an additional 66,450 shares during the period. Renaissance Technologies LLC raised its stake in shares of Versartis by 161.4% in the fourth quarter. Renaissance Technologies LLC now owns 49,400 shares of the biopharmaceutical company’s stock worth $736,000 after buying an additional 30,500 shares during the period. Metropolitan Life Insurance Co. NY raised its stake in shares of Versartis by 22.5% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 23,257 shares of the biopharmaceutical company’s stock worth $347,000 after buying an additional 4,270 shares during the period. Finally, Teachers Advisors LLC raised its stake in shares of Versartis by 15.0% in the fourth quarter. Teachers Advisors LLC now owns 50,368 shares of the biopharmaceutical company’s stock worth $750,000 after buying an additional 6,573 shares during the period. Hedge funds and other institutional investors own 78.24% of the company’s stock.
Versartis Company Profile
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.